Results for 'Nursing & Care Teams'
Follow
Tom Caravela
MSL Evolution: New Trends and Titles That May Emerge
digital marketing strategies, SEO best practices, content marketing tips, social media optimization, keyword research tools
The COVID-19 pandemic has clearly had a profound impact on Field Medical Affairs. Has the Medical Science Liaison role changed forever? What new titles, trends and opportunities might emerge as a result of the new age for Field Medical and the evolution of the Medical Science Liaison? Is virtual en…
Apr 5th • 1 min read
Bridget Rasmusson
6 Tips to Ace Your Next MSL Interview!
digital marketing, content optimization, search engine ranking, keyword research, on-page SEO
As a Medical Affairs-focused recruitment firm, we see MSL interview "wins" and slip-ups on a daily basis. From our experience working with candidates across all therapeutic areas and across the entire United States, I've noticed a few trends that might help you get that next interview "win" under yo…
Sep 28th • 1 min read
Bridget Rasmusson
Positioning Yourself to Become an MSL in 2022
MSL role, clinical background, academic background, research background, industry, MSL Society, conference, scientific expert, therapeutic expertise, pharma companies
After attending the MSL Society’s 9th annual conference in Vegas Last week, I have taken some time to reflect on inquiries our team received about how to effectively step into the MSL role from a clinical, academic, or research background. Industry is a tough nut to crack, but it is absolutely…
Dec 21st • 10 mins read
Ioannis Tsagakis and Maria Papatriantafyllou
Safeguarding cancer research funding by European charities amidst the COVID-19 pandemic
cancer charities, cancer research, COVID‐19, funding, pandemic, policy, AECC, AIRC
The COVID-19 outbreak has had a significant impact on cancer research and cancer care. European cancer charities are required to reassess their strategies. There is a need to safeguard income and provide support to cancer researchers. It is crucial to sustain cancer research funding during thes…
Nov 22nd • 3 mins read
Ashley Woolmore , Dirk Arnold , Jean‐Yves Blay , Christian Buske , Alfredo Carrato , Winald Gerritsen , Marc Peeters , Jesus Garcia‐Foncillas , David Kerr
The Oncology Data Network (ODN): Methodology, Challenges, and Achievements
The oncology data network, ODN
The Oncology Data Network (ODN) aims to create a collaborative infrastructure for precision medicine, established in over seven European countries with 124 cancer centers. The ODN collects concise data on cancer medicine use, adhering to EU GDPR regulations, and has a central European Data Wareho…
May 21st • 8 mins read
Ruben Van Paemel, Roos Vlug, Katleen De Preter, Nadine Van Roy, Frank Speleman, Leen Willems, Tim Lammens, Geneviève Laureys, Gudrun Schleiermacher, Godelieve A. M. Tytgat, Kathy Astrahantseff, Hedwig Deubzer, Bram De Wilde
The pitfalls and promise of liquid biopsies for diagnosing and treating solid tumors in children: a review
Liquid biopsies, Pediatric solid tumors, Cell-free DNA profiling
Cell-free DNA profiling via blood samples is emerging as a non-invasive method for cancer genomic characterization. Liquid biopsies are set to be integrated into pediatric cancer clinical trials, offering benefits such as earlier therapy response monitoring and detection of residual disease.…
Jan 3rd • 10 mins read
R. Kurzrock, L.A. Gurski, R.W. Carlson, D.S. Ettinger, S.M. Horwitz, S.K. Kumar, L. Million, M. von Mehren, A.B. Benson III
Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals
oncology, guidelines, off-label drug use
The analysis reviewed 113 NCCN recommendations, focusing on 44 off-label uses of drugs. 14 of these off-label recommendations were later FDA-approved or backed by RCT data. 13 recommendations were minor extrapolations from the FDA label or actually on-label. Of the remaining 17 extrapolations…
Aug 2nd • 8 mins read
Envision Pharma Group
Medical affairs: The power behind redefining commercialization
Medical affairs commercialization, integrating science in pharma, redefining medical affairs roles, strategic medical affairs leadership, early engagement with payers, pharmaceutical commercialization strategies, upskilling in medical affairs, medical aff
In March 2024, Envision Pharma Group held a Medical Affairs Professional Society (MAPS) Americas roundtable with leaders discussing the role of science in commercialization strategies and the importance of integrating robust scientific understanding into the commercial journey. Envision revisite…
Aug 2nd • 3 mins read
Envision Pharma Group
AI-powered real-world evidence: Strategically enhancing value and access
Oncology, Clinical Development, Targeted Therapy, Immunotherapy, Genomic Profiling, CAR-T Cell Therapy, Precision Medicine
Real-world evidence (RWE) complements traditional randomized controlled trials by providing insights from diverse data sources, helping healthcare decision-makers with coverage, reimbursement, and treatment guidelines. Artificial intelligence (AI) and natural language processing (NLP) are pivotal…
Aug 22nd • 5 mins read